Serum Lactate Dehydrogenase Values Research Articles

Prognostic value of serum lactate dehydrogenase and serum ferritin for abdominal neuroblastoma in children

Backgrounds: For decades, age, MYCN status, stage, and histology have been used as neuroblastoma risk factors. Serum Lactate dehydrogenase (LDH) and ferritin are reproducible, easy to obtain, and prognostic, but they are never used in risk stratification. Purpose/Objective: The purpose of this study was to find out the prognostic value of serum LDH and ferritin in children with abdominal neuroblastoma. Materials/Methods: Nine children with abdominal neuroblastoma from 2020-2021 in four tertiary centers of Dhaka, who treated according to Socie’te’ Internationaled’OncologiePe’diatrique selected as study population and divided into low and high-risk groups. Age, sex, stage, histology, serum LDH, serum ferritin and events were analyzed using SPSS 22. Survival was calculated by Kaplan-Meier procedure Results: Sensitivity, specificity, positive predictive value and negative predictive value of serum LDH were 100%, 85.7%, 66.7% and 100% respectively in the prognosis of abdominal neuroblastoma in children at a cut-off point =1527.5. Sensitivity, specificity, positive predictive value, and negative predictive value of serum ferritin were 100%, 71.4%, 50% and 100% respectively in the prognosis of abdominal neuroblastoma in children at a cut-off point=581.There was no significant difference between the survival curves of both risk groups (p= 0.180) and between serum ferritin >581 and £581 group (p= 0.089) according to log rank test. But there was significant difference between the survival curves of LDH >1527 and LDH £1527.5 group according to log rank test (p= 0.027). Conclusion: Analysis of this study revealed that the risk of a worse event for children with abdominal neuroblastoma was greater and outcome was also worse for patients with serum LDH >1527.5 IU/L and serum ferritin >581 ng /ml. These markers can also be used for risk stratification in low to middle income countries. But further multi-centered study with longer period of follow up on larger sample size will be required to demonstrate the independent prognostic value of serum LDH and ferritin for abdominal neuroblastoma in children. Journal of Paediatric Surgeons of Bangladesh (2019) Vol. 10 (1 & 2): 43-48

Laboratory Diagnostics Accuracy for COVID-19 versus Post-COVID-19 Syndrome in Lung Disease Patients with Multimorbidity.

The laboratory tests and identification of risk factors such as comorbidities are essential in the management, treatment and prognosis of patients with chronic respiratory diseases. Performing rigorous monitoring among patients with post-COVID-19 syndrome and early identification of risk factors associated with poor prognosis are crucial in improving patient outcomes. In the present study, 182 patients diagnosed with COVID-19 and PCI during 2020-2022 were included. A clinical and epidemiological evaluation was performed for each patient. Laboratory tests at admission included complete blood count, Erythrocyte Sedimentation Rate (ESR) and biochemical tests. Receiver operating curve (ROC) and area under the curve (AUC) were calculated to compare the diagnostic performance of each parameter. Regarding comorbidities, arterial hypertension, diabetes mellitus and obesity were the most frequent ones. In the case of chronic lung diseases, asthma and Chronic Obstructive Pulmonary Disease (COPD) were the most frequent. Pleurisy was found especially in patients with PCI Variations in serum LDH values were observed, especially in severe forms of COVID-19 in 2020, with a mean value of 481.44 U/L, compared to patients with PCI, whose mean values (122 U/L) were within the biological range of reference. High neutrophil/lymphocyte ratio (NLR) values quantified in this study were especially associated with moderate and severe forms of COVID-19 and also PCI. The Spearman correlation coefficient was determined to measure the correlations between the clinical parameters of all investigated subjects. A value of p < 0.05 was considered statistically significant. The statistical results indicated that serum lactate dehydrogenase (LDH), glucose and C-reactive protein (CRP) are sensitive markers with a diagnostic role in COVID-19, and lymphocyte (Ly) count, CRP, ESR and glucose were evidenced to be target markers in PCI. LDH values were observed to be statistically significant (p < 0.005) in patients with COVID-19 and obesity evaluated in 2021, while Ly count was statistically significant (p = 0.05) in patients with PCI and arterial hypertension. Regarding comorbidities, it has been observed that obesity, arterial hypertension and cardiovascular diseases represent risk factors in COVID-19/PCI, associated especially with the severe forms of the disease.

Correlation with serum Lactate dehydrogenase level and Hematological parameters before and after induction of remission in childhood Acute lymphoblastic leukemia- A prospective study

The relationship between serum LDH (lactate dehydrogenase) and the course of neoplasia had been well established in different studies. It might be a promising tool as assessing serum is easy, readily available and cheap in the prognosis of childhood Acute Lymphoblastic Leukemia (ALL). This study is aimed to evaluate the role of serum LDH before and after induction of remission in childhood ALL. This study was conducted at the Department of Pediatrics, Rajshahi Medical College Hospital, and Rajshahi for a period of two years. Total 30 children aged from 1-12 years newly diagnosed cases of ALL were included. Each patient underwent clinical evaluation and relevant investigations. All information was recorded in a separate case record form. Collected data were analyzed using the statistical software SPSS 23. Mean age of the studied children was 5.03±3.17 years. Male children were 66.7% and female children were 33.3%. Mean value of serum LDH was significantly lower at 29th days of induction of remission compared to the value before chemotherapy (432.40±310.52 U/L vs. 829.10±345.58 U/L, p&lt;0.05). Mean peripheral blast cell also reduced after chemotherapy (30.03±16.41% Vs. 0.37±0.96%). Pearson correlation model showed strong positive correlation between LDH level and bone marrow blast cell at both before and after chemotherapy (r&gt; +0.75, p&lt;0.001). This study observed significant reduction of LDH after chemotherapy and positive linear relation with peripheral blast cells. TAJ 2023; 36: No-2: 83-92

Predictive value of serum lactate dehydrogenase on prognosis of patients with paraquat poisoning

Objective: To investigate the predictive value of serum lactate dehydrogenase (LDH) in the prognosis of patients with paraquat (PQ) poisoning, and to provide evidence for early prognosis assessment. Methods: In February 2022, 50 patients with PQ poisoning who completed serum LDH detection admitted to the Department of Emergency Medicine, the First Affiliated Hospital of Wenzhou Medical University from January 2012 to December 2021 were selected as the observation group, and 50 healthy physical examination personnel were randomly selected as the control group. Patients with PQ poisoning were divided into survival group and death group according to the prognosis, and the differences of blood routine routine, liver and kidney function and other indicators in the first admission between the two groups were compared. Multivariate logisitic regression model was established, ROC curve was drawn, and the influencing factors of prognosis of patients with PQ poisoning were analyzed. Results: Compared with the control group, the white blood cell count (WBC), total bilirubin (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), LDH, glucose (GLU) and creatinine (Cr) in observation group were significantly increased, while albumin (ALB) and total cholesterol (TC) were significantly decreased (P<0.05). Univariate analysis showed that WBC, elevated LDH (>247 U/L), TBil, ALT, AST and Cr were significantly different between PQ poisoning survival group and death group (P<0.05). Multivariate logisitic regression analysis showed that elevated serum LDH was an independent risk factor for the prognosis of PQ poisoning patients (OR=9.95, 95%CI: 1.34-73.82, P=0.025). The area under the ROC curve of LDH was 0.811 (95%CI: 0.692-0.930). When the cut-off value was 340 U/L, the sensitivity was 0.889 and the specificity was 0.719. Log-rank test showed that there was a statistically significant difference in survival rate between the normal LDH group and the elevated LDH group (P=0.001) . Conclusion: Serum LDH has a good predictive value in evaluating the prognosis of patients with PQ poisoning. Elevated LDH is a risk factor for poor prognosis of patients with PQ poisoning.

Testicular Effect of Selenium Nanoparticles on Monosodium Glutamate Induced Alteration in Male Albino Rats.

&lt;b&gt;Background and Objective:&lt;/b&gt; The flavor enhancer Monosodium Glutamate (MSG) is mostly utilized in Asian and West African cuisines, especially in West African and Asian dishes. However, due to its availability, largely without labeling, in many food products, unintentional overuse of this food additive may occur. The objective of this study was to find out how selenium nanoparticles affected the toxicity of MSG in male albino rats' testicles. &lt;b&gt;Materials and Methods:&lt;/b&gt; As 35 Wistar male rats partitioned into 5 groups: G1: Control rats, G2: Received Se-NPs at 0.4 mg kg&lt;sup&gt;1&lt;/sup&gt; b.wt., orally, G3: Injected with MSG at a daily dose of 4 g kg&lt;sup&gt;1&lt;/sup&gt; b.wt., intraperitoneally (IP), G4: Ingested a daily oral dose of Se-NPs for 7 successive days and on the 7th day, received the first dose of MSG IP 4 g kg&lt;sup&gt;1&lt;/sup&gt; b.wt., then received both treatments till the end of the study and G5: Administered a daily oral dose of 4 g kg&lt;sup&gt;1&lt;/sup&gt; MSG, followed by Se-NPs at a daily dose of 0.4 mg kg&lt;sup&gt;1&lt;/sup&gt; b.wt., the experiment continued for 28 days. Serum testosterone hormone, Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), the levels of serum lipid peroxidation (MDA), reduced Glutathione (GSH), Glutathione Peroxidase (GSH-Px), superoxide dismutase (SOD) and Lactate Dehydrogenase (LDH) were estimated and samples from testis were separated for histological analysis. &lt;b&gt;Results:&lt;/b&gt; The MSG treatment induced a significant decline in the values of serum testosterone, FSH, LH, GSH, GSH-Px and SOD. It also increased the values of serum MDA and LDH and spermatic arrest. While, the administration of Se-NPs orally before MSG treatment resulted in a decline in the values of serum MDA and LDH, an elevation in the values of serum GSH, GSH-PX and SOD, testosterone, FSH, LH and reappearance of sperm. &lt;b&gt;Conclusion:&lt;/b&gt; The use of Se-NPs as a protector exhibited more improvement in values of estimated hormones and oxidative stress markers than using it as a therapy.

Serum LDH levels may predict poor neurological outcome after aneurysmal subarachnoid hemorrhage

IntroductionSerum lactate dehydrogenase (LDH) levels are often elevated in cardiovascular diseases. Their prognostic role after subarachnoid hemorrhage (SAH) remains poorly evaluated.MethodsThis is a retrospective single-center study of patients with non-traumatic SAH admitted to the intensive care unit (ICU) of an University Hospital from 2007 to 2022. Exclusion criteria were pregnancy and incomplete medical records or follow-up data. Baseline information, clinical data, radiologic data, the occurrence of neurological complications as well as serum LDH levels during the first 14 days of ICU stay were collected. Unfavorable neurological outcome (UO) at 3 months was defined as a Glasgow Outcome Scale of 1–3.ResultsFive hundred and forty-seven patients were included; median serum LDH values on admission and the highest LDH values during the ICU stay were 192 [160–230] IU/L and 263 [202–351] IU/L, respectively. The highest LDH value was recorded after a median of 4 [2–10] days after ICU admission. LDH levels on admission were significantly higher in patients with UO. When compared with patients with favorable outcome (FO), patients with UO had higher serum LDH values over time. In the multivariate logistic regression model, the highest LDH value over the ICU stay (OR 1.004 [95% CI 1.002 – 1.006]) was independently associated with the occurrence of UO; the area under the receiving operator (AUROC) curve for the highest LDH value over the ICU stay showed a moderate accuracy to predict UO (AUC 0.76 [95% CI 0.72–0.80]; p < 0.001), with an optimal threshold of > 272 IU/L (69% sensitivity and 74% specificity).ConclusionsThe results in this study suggest that high serum LDH levels are associated with the occurrence of UO in SAH patients. As a readily and available biomarker, serum LDH levels should be evaluated to help with the prognostication of SAH patients.

Expression of Concern: Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Expression of Concern: Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Diagnostic value of serum LDH in children with refractory Mycoplasma pneumoniae pneumoniae: A systematic review and meta-analysis.

To investigate the relationship between serum Lactate dehydrogenase (LDH) and refractory Mycoplasma pneumoniae pneumonia (RMPP) in juvenile individuals. Search Chinese databases and English databases. The retrieval time limit is from the establishment of the database to 2022-04-27. And screening and inclusion of relevant diagnostic test literature. The QUADAS-2 method was used to evaluate the quality of the included literature. The random effects model was used to combine sensitivity, specificity, likelihood ratio, diagnostic odds ratio, summary receiver operating characteristic curve, and area under summary receiver operating characteristic curve to evaluate the prediction value of LDH for RMPP. Subgroup analyses were used to explore sources of heterogeneity. ① A total of 29 literatures that met the criteria were included in the study, and the quality of the literature was medium and high, with a total of 702,2 patients. ② The combined sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve of the studies were: 0.75 (95% CI = 0.73-0.76), 0.73 (95% CI = 0.72-0.74), 3.61 (95% CI = 2.86-4.56), 0.30 (95% CI = 0.23-0.39), 13.04 (95% CI = 8.24-20.63), and 0.85(95% CI = 0.82-0.88). ③ The results of subgroup analysis showed that Compared with the subgroup with LDH threshold ≤400 IU/L, the AUC increased from 0.84 (95% CI = 0.80-0.87) to 0.89 (95% CI = 0.86-0.91). The serum LDH has good accuracy for the diagnosis of RMPP and can serve as a diagnostic marker for RMPP.

Serum lactate dehydrogenase is associated with impaired lung function: NHANES 2011-2012.

Serum lactate dehydrogenase levels reflect disease status in a variety of organs, but its role in indicating pulmonary function is not yet clear. Therefore, this study explored the correlation between pulmonary function and serum lactate dehydrogenase, and investigated thresholds for changes in pulmonary function indicators in the total population as well as in different strata of the population. Based on data from the National Health and Nutrition Examination Survey (NHANES) 2011-2012 (n = 3453), univariate and stratified analyses were performed to investigate factors associated with pulmonary function, and multiple regression analysis was used to further investigate the specific relationship with serum lactate dehydrogenase. Smoothed curve fitting, threshold effect and saturation effect analysis were used to explore the threshold level of serum lactate dehydrogenase at the onset of changes in pulmonary function indicators. Adjusted smoothed curve fit plots showed a linear relationship between serum lactate dehydrogenase levels and forced vital capacity and forced expiratory volume in one second: for each 1 U/L increase in serum lactate dehydrogenase levels, forced vital capacity decreased by 1.24 mL (95% CI = -2.05, -0.42, P = 0.0030) and forced expiratory volume in one second by 1.11 mL (95% CI = -1.82, -0.39, P = 0.0025). Serum lactate dehydrogenase was negatively and linearly correlated with pulmonary function indices in the total population analyzed. Based on the total population and different population stratifications, this study determined the threshold values of serum lactate dehydrogenase at the onset of decline of pulmonary function in different populations. This provides a new serological monitoring indicator for patients suffering from respiratory diseases and has implications for patients with possible clinical impairment of pulmonary function. However, our cross-sectional study was not able to determine a causal relationship between these two factors, and further research is needed.

The Role of Serum Lactate Dehydrogenase in Etiological Diagnosis of Macrocytic Anemia

Background: Macrocytic anemia is common and is characterized by decreased hemoglobin levels with elevated Mean Corpuscular Volume (MCV), due to a range of diseases and divided into Megaloblastic and Non-megaloblastic anemia. Serum vitamin B12 and folic acid tests are usually performed but they are limited by their low sensitivity and specificity. To confirm diagnosis of macrocytic anemia bone marrow examination is required but it is invasive procedure. Vitamin B12 and/or B9 deficiency leads to a defect in DNA synthesis leading to ineffective erythropoiesis and intramedullary hemolysis in patients of megaloblastic anemia, this leads to increased serum LDH (Lactate Dehydrogenase) and unconjugated bilirubin. Aims of study: This study was carried out to evaluate the role of serum LDH in the distinction between megaloblastic and non-megaloblastic anemia, and to study the correlation between serum LDH and MCV Patient and Methods: The study included 60 patients with non-regenerative macrocytic anemia (We exclude patients with regenerative macrocytic anemia because elevated reticulocytes leads us to hymolysis anemia or bleeding and it’s not a diagnostic problem(. Complete blood count, biochemical investigation, peripheral blood examination, reticulocyte count, bone marrow examination was performed in all cases Results: The most common cause of macrocytic anemia was Megaloblastic anemia (65%). The other causes were primary bone marrow disorders (35%). There was a significant difference in the mean values of serum LDH and MCV between two groups ( megaloblastic and non-megaloblastic anemia). When LDH&gt;2076.5 IU/L, there is more probability of having megaloblastic anemia than non-megaloblastic anemia but when LDH&gt;2076.5 and MCV&gt;109.45 with bilirubin&gt; 1.2mg/dl will must more probably not have non-megaloblastic anemia (the specificity was 100%), all three parameters combined together can be used as screening test to distinguish between the 2 groups of macrocytic anemia (megaloblastic and non-megaloblastic) without necessity of bone marrow aspiration in patients of non- regenerative macrocytic anemia. Present study had also shown that there were a positive relationship between serum LDH and MCV (r=+0.613).

Lactate dehydrogenase (LDH) and evaluation of response to breast cancer chemotherapy

Breast cancer is the leading cause of cancer death in women worldwide. The aim of this study was to determine the value of post-therapy serum LDH in assessing response at the completion of chemotherapy in breast cancer patients. This was a prospective cross-sectional study with data collection from May 2019 to November 2020, at the University Hospital of Bogodogo and at the SANDOF Polyclinic. We performed the LDH assay on serum from patients at the end of breast cancer chemotherapy who were at least 18 years old. Thirty (30) patients were included, with a mean age of 47.47 ± 2.10 years. Based on RECIST criteria, 46.67% had a successful response to chemotherapy, while 53.33% had a poor response. The mean post-therapy serum LDH was 256.15±25.99 U/L and 46.67% of patients had elevated serum LDH. Mean serum LDH was significantly higher in patients with a personal history of breast cancer (p=0.0198), increased CA 15-3 (p=0.0489) and poor response to chemotherapy (p=0.0291). Serum LDH was significantly higher in patients with a poor response to chemotherapy. Further studies are required to establish a more reliable correlation between serum LDH levels and response to breast cancer chemotherapy.

The Prognostic Role of the C-Reactive Protein and Serum Lactate Dehydrogenase in a Pediatric Series of Bone Ewing Sarcoma.

Simple SummaryEwing sarcoma is a rare and aggressive tumor of childhood and adolescence. Over the years, different prognostic factors have been explored to stratify high-risk patients. The roles of C-reactive protein (CRP) and serum lactate dehydrogenase (LDH) as potential new prognostic factors would be a useful and simple for risk stratification, but they have rarely been investigated. In our work, we analyze the role of LDH and CRP as prognostic factors in a population of pediatric and adolescent patients affected by Ewing sarcoma. Our study confirms the potential prognostic role of LDH at diagnosis as an independent prognostic factor. LDH evaluation is not expensive, and it can be beneficial for developing countries where diagnostic and staging resources in the pediatric oncology field are poor. Background: Ewing sarcoma (ES) is a rare and aggressive pediatric cancer. Numerous studies have attempted to identify new prognostic biomarkers. The predictive value of serum LDH and CRP has not been clearly described, to date. Methods: The objective of our retrospective study was to investigate the prognostic value of LDH and CRP levels and their association with overall survival in a series of ES patients. Results: Between 2004 and 2019, 89 ES patients were included. In a univariable analysis, high levels of LDH and CRP were associated with the worst prognosis. In a multivariable analysis, only higher LDH values remained associated with a lower survival. The high-LDH-level group experienced all 21 deaths registered in our population (24%) and about 90% of disease progressions. The 5-year overall survival was 66.4% in the high-LDH-level group, while no deaths were observed in the low-LDH-level group. The 5-year progression-free survival was 57.9% in the high-LDH-level group versus 80.4% in the low-LDH-level group. Conclusions: In our study, LDH levels at diagnosis were strongly correlated with the prognosis, and they might be considered a prognostic factor in Ewing sarcoma. The LDH value, along with its very low cost and its reproducibility in almost all centers, make it suitable as a potential prognostic biomarker in clinical practice.

Utility of Routine Serum LDH After HeartMate 3 Left Ventricular Assist Device Implantation

<h3>Purpose</h3> This study aims to evaluate the fluctuation of serum Lactate Dehydrogenase (LDH) in patients who are post-HeartMate 3 (HM3) Left Ventricular Assist Device (LVAD) implantation and to determine if routine monitoring of serum LDH values has changed management of patients, outcomes, or detected any pump thrombosis events. <h3>Methods</h3> This is a retrospective cohort study reviewing the electronic medical records of forty-eight HM3 LVAD patients at a tertiary care center in New Jersey, USA with implant dates ranging from 2017 to 2021. For each of these patients, serum LDH values were obtained including baseline values pre-implantation as well as fixed points in time post-operatively, specifically one week, one month, three months, six months, one year, one and a half years, and two years post-implantation as applicable for each patient. Each abnormal LDH value underwent further chart analysis to see if there was any change in clinical status, outcomes, management, or pump thrombosis event. An abnormal serum LDH value was defined as greater than 2.5 times the upper limit of normal, which has been standard practice to evaluate for pump thrombosis and/or hemolysis. <h3>Results</h3> Chart review of forty-eight HM3 LVAD patients showed that routine monitoring of serum LDH values did not change clinical outcomes or management of patients. Forty-six out of forty-eight patients did not have any recorded serum LDH value greater than 2.5 times the upper limit of normal post-implantation. The two patients with elevated serum LDH values post-operatively were never stable enough to be discharged from the hospital and expired shortly after implantation. There was also a 0% rate of pump thrombosis. <h3>Conclusion</h3> Routine monitoring of serum LDH in patients who are post-HM3 LVAD implantation does not change management or outcomes in asymptomatic patients. Therefore, ending routine monitoring of serum LDH eliminates unnecessary blood draws for patients and could represent a savings in healthcare costs as well as resources.

To Study of Serum Lactate Dehydrogenase in Chronic Obstructive Pulmonary Disease Patients.

Background: To Study of serum lactate dehydrogenase in Chronic Obstructive Pulmonary Disease Patients&#x0D; Methods: It is a prospective study of 100 subjects divided into two groups including 50 healthy controls and 50 cases of COPD.&#x0D; Results: The statistically significant increased value of serum lactate dehydrogenase in cases as compared to control group.&#x0D; Conclusion: LDH level was significantly higher in COPD patients as compare to healthy control.&#x0D; Keywords: COPD, Lactate dehydrogenase, Pulmonary.

Serum lactate dehydrogenase in the prognostic assessment of patients with oral squamous cell carcinoma.

Lactate dehydrogenase (LDH) has been proven to be a diagnostic marker in oral squamous cell carcinoma (OSCC). However, the prognostic value of serum LDH in OSCC is yet to be explored. The purpose of this study is to correlate the level of serum LDH with the degree of OSCC and to evaluate the role of serum LDH as a prognostic marker in OSCC. The investigators designed and implemented a prospective cohort study composed of patients with OSCC (n = 66) sub-grouped as follows: 2A-well-differentiated (n = 22), 2B-moderately differentiated (n = 22), 2C-poorly differentiated OSCC (n = 22), and normal healthy controls (n = 40). The primary outcome variable was the serum LDH measured at baseline (pre-treatment) and 2 and 12 months post-treatment in OSCC patients. The statistical analysis was performed using the student t-test and analysis of variance, and the P value was set at 0.05. The habit of alcohol consumption alone as a single habit was found only in males (17.5%) (P = 0.3343), whereas betel quid chewing was more common among females (P = 0.0182). A significant difference was observed in the mean serum LDH between OSCC subjects (pre-treatment) (831.56 ± 93.43 IU/L) and controls (188.82 ± 25.53 IU/L), P < 0.00001. The baseline serum LDH was significantly higher in subgroup 2C (933.41 ± 46.1969 IU/L) than in the 2A (742.59 ± 46.5676 IU/L) and 2B (818.68 ± 58.1643 IU/L) subgroups (P = 0). There was a significant decline in the serum LDH within 2 months after treatment, and a further decrement was observed during a 12-month follow-up among the survivors of all three subgroups; P < 0.00001. Serum LDH can play a dual role as a reliable indicator of the degree of OSCC for decision-making in treatment modalities and as a prognostic marker of response to therapy.

Relationship between LDH and Mg in Monitoring of Hematological and Non-Hematological Malignant Diseases

Relationship between LDH and Mg in Monitoring of Hematological and Non-Hematological Malignant DiseaseAurelian Udristioiu,Titu Maiorescu University of Bucharest, Faculty of Medicine, Department of Molecular BiologyABSTRACTBackgroundMagnesium, which is the second most abundant into-cellular cation after potassium, plays a key role in regulating many cellular functions and enzymes, including ion channels, metabolic cycles, and signaling pathways.Aim of this study was to evaluate the correlation between the serum levels of lactate dehydrogenase (LDH) and magnesium (Mg) in patients diagnosed with hematological and non-hematological malignant diseases.MethodWe analyzed a cohort of patients (n = 75) comprising males (n = 36) and females (n =39) with a mean age of 57 years, who had cancer and were admitted to the oncology department. The biochemical parameters were measured running a Vitros 250 dry chemistry analyzer (Johnson & Johnson, USA) using the slides for multi-layer spectro-photometry measurements.These patients were closely monitored twice a week during treatment with specific cytostatic drugs and once a week during consolidation therapy, using specific tests for different types of cancer. In addition, with the cooperation of physicians and patients, they were performed along with hematological and biochemical tests, CBC with differential count and LDH and serum Mg levels, which can serve as markers for monitoring the progression of malignancies.Among the patients, 5 patients were diagnosed with lung cancer, 11 patients were diagnosed with breast cancer, 14 patients were diagnosed with colorectal cancer, 43 patients were diagnosed with chronic lymphocytic leukemia (CLL), 1 patient was diagnosed with acute promyelocytic leukemia (LAM-3) and 1 patient was diagnosed with chronic monocytic leukemia (CML).The CBC with the differential count, biochemistry samples, body radiography, ultrasound and computed tomography (CT) were used for the patient to establish the type of cancer diseases. An initial panel of monoclonal antibodies was used to determine the immune phenotypes of the subgroups of differentiated T cells and B cells. The diagnosis of LAM-3 was made based on blood smears, the examination of bone marrow (BM) aspirates, the evaluation of promyelocytes, (greater than 30% in BM), and the presence of a specific immune phenotype.ResultsThe results were interpreted for each patient based on medical history, clinical and para-clinical examinations and other signs of malignant diseases. Among the patients in this study, 55 patients (73%) exhibited normal serum levels of Mg (normal range value = 1.60-2.3 mg/dL; mean value = 2.2 mg/dL; SD = 0.2; p = 0.02) following cancer therapy. Six patients (8%) exhibited low levels of Mg (range = 0.60-1.50 mg/dL; mean value = 1.05 mg/dL). However, 12 patients (16%) displayed high levels of serum Mg (range =2.6-3.27 mg/dL; mean value = 2.89 mg/dL). The levels of serum lactic dehydrogenase (LDH) were also evaluated in patients newly diagnosed with cancer and in patients with unfavorable responses to the cancer therapy (range = 240-1330 U/L; mean value = 787 U/L; SD =1.33; p = 0.002; normal values 135-225 U/L), (Table 1).DiscussionsThe serum Mg level is increased via Mg²+ release from malignant tissues in patients with malignant disease prior to treatment with cytostatic drugs. In the different malignant diseases, the serum Mg values were high, normal or low, independent of the serum LDH values. The LDH levels remained elevated after initial cytostatic treatment until cancer remission.The number of chromosome copies in malignant tumors can be correlated with the total serum LDH values. LDH levels in cancer patients are elevated due to high levels of LDH-3 isoenzyme in patients with malignancies and high levels of LDH-4 and LDH-5 isoenzymes, elevated patients with cancer of liver, muscle, lung and tissue tissues. conjunctive. High concentrations of serum LDH damage the cell membrane. Thereafter, malignant cells become invasive and metastasizes.ConclusionsNormal levels of Mg with moderately increased LDH levels were observed in all patients who had cancer that was in the regression phase following good responses to a specific cancer therapy. Low levels of Mg with high levels of serum LDH were observed in all patients with poor prognosis and metastases. [Display omitted] DisclosuresNo relevant conflicts of interest to declare.

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Preoperative serum lactate dehydrogenase level predicts progression and prognosis in patients with glioma

BackgroundTo evaluate the value of serum Lactate Dehydrogenase (LDH) level in predicting recurrence and the overall survival (OS) of glioma patients. Materials and methodsA total number of 216 patients with glioma in our institution were retrospectively recruited to analyze the relationship between preoperative serum LDH level and prognosis. ResultsOverall, the median age of patients was 46.0 (31.0–57.0) years old; 53.7% (116 of 216) of the enrolled patients were male. Multivariate analysis revealed that serum LDH level (odds ratio [OR] = 0.97, 95% confidence interval [CI] = 0.96–0.98, P < 0.001) and World Health Organization (WHO) grade (grade II: OR = 19.64, 95%CI = 5.56–69.35, P < 0.001; grade III: OR =1 9.50, 95%CI = 7.08–53.73, P < 0.001; grade IV: OR = 15.23, 95%CI = 4.94–46.97, P < 0.001) were significant and independent of 1-year Progression-free survival (PFS) after adjusting for confounders. The predictive performance of serum LDH level was represented with area under curve (AUC) = 0.741, 95%CI = 0.677–0.798. Multivariate Cox analysis revealed that LDH level (hazard ratio [HR] = 2.56, 95%CI = 1.59–4.15, P < 0.001) and WHO grade (grade II: HR = 4.58, 95%CI = 0.56–37.23, P = 0.155; grade III: HR = 16.35, 95%CI = 2.16–123.80, P = 0.007; grade IV: HR = 42.13, 95%CI = 5.83–304.47, P < 0.001) remained associated with survival at 2-year follow-up. At 3-year follow-up, lymphocyte count (HR = 0.68, 95%CI = 0.51–0.91, P = 0.008), LDH level (HR = 2.21, 95%CI = 1.40–3.49, P = 0.001), and WHO grade (grade II: HR = 1.44, 95%CI = 0.44–4.68, P = 0.543; grade III: HR = 4.99, 95%CI = 1.68–14.87, P = 0.004; grade IV: HR = 16.96, 95%CI = 6.13–46.93, P < 0.001) remained associated with survival in multivariate Cox analysis. ConclusionOur study demonstrated that preoperative serum LDH level could serve as a reliable indicator for predicting prognosis of glioma patients. Further multicenter studies are still required to verify our findings.

27. PREDICTIVE VALUE OF LACTATE DEHYDROGENASE FOR POOR MATERNAL AND PERINATAL OUTCOMES IN PATIENTS WITH PRE-ECLAMPSIA: A META-ANALYSIS

Background: A large number of studies have reported the relationships between serum lactate dehydrogenase (LDH) and prognosis of pre-eclampsia. However, the result is still controversial and no consensus has been reached. Objective: The aim of the study was to find out the role of serum LDH in prediction of poor maternal and perinatal outcomes in patients with pre-eclampsia. Methods: We performed a systematic computerized search for eligible articles from PubMed, Europe PMC, ProQuest, EBSCOhost, and Google Scholar databases from inception to January 2021. The pooled odds ratio (OR) and 95% confidence intervals (CIs) of all events of interest and event-free subjects were obtained to assess the predictive value of serum LDH in predicting composite poor outcomes. Results: A total of 11 studies that assessed patients with pre-eclampsia were included. Overall, elevated serum LDH level in pre-eclamptic patients was associated with poor maternal and perinatal outcomes [pooled OR: 7.92 (95% CI = 5.75–10.93); pooled OR: 8.08 (95% CI = 4.40–14.83) respectively]. Subgroup analyses showed that elevated LDH also increased risk of placental abruption, disseminated intravascular coagulation, acute renal failure, eclampsia, and HELLP syndrome. The resulting P-value showed no heterogeneity among articles (P &gt; 0.01). No evidence of asymmetry was shown in the funnel plot, thus no publication bias existed in the included studies. Conclusions: This meta-analysis demonstrates that elevated serum LDH level is apparently associated with poor outcomes in patients with pre-eclampsia and serum LDH could be a prognostic biomarker for pre-eclamptic patients.

Evaluation the relationship of left ventricular global longitudinal strain and laboratory parameters in discharged patients with COVID-19: a follow-up study.

Background: The novel coronavirus infection (COVID-19) disease has spread rapidly and posed a great threat to global public health. The laboratory parameters and clinical outcomes of the disease in discharged patients remain unknown. In this study, we aimed to investigate the laboratory and echocardiographic findings of patients with COVID-19 after discharge and the relation between left ventricular global longitudinal strain (LVGLS) and inflammatory parameters in discharged patients. Methods: A total of 75 patients recovering from COVID-19 as the study group were prospectively recruited from the COVID-19 outpatient clinic for their follow-up visits at a median 6 months after discharge. Patients were classified into groups according to pneumonia severity and impairment in LVGLS. Laboratory findings of patients both at admission and after discharge were evaluated and the relation with pneumonia severity at admission and LVGLS after discharge were analyzed. Results: Serum ferritin, lactate dehydrogenase (LDH) and prohormone B-type natriuretic peptide (pro-BNP) levels after discharge were significantly higher in the study group than the control group (n = 44). Ferritin was found to be related to pneumonia severity. Serum ferritin and LDH values after discharge were significantly higher in patients with impaired LVGLS than those with preserved. There was a significant correlation between LVGLS, serum ferritin and LDH values after discharge (r = −0.252, p = 0.012; r = −0.268, p = 0.005, respectively). Conclusions: Clinicians should pay close attention to the serum ferritin and LDH levels in discharged patients for predicting the severity of COVID-19 disease and early identification of subclinical left ventricular myocardial dysfunction.